Barton P. Bandy - 31 Jan 2022 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
President and CEO, Director
Signature
/s/ Barton P. Bandy
Issuer symbol
RSLS
Transactions as of
31 Jan 2022
Transactions value $
-$10,155
Form type
4
Filing time
02 Feb 2022, 15:32:03
Previous filing
28 Jan 2022
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Sale -$10.2K -8.32K -0.99% $1.22 837K 31 Jan 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 22, 2021, Mr. Bandy was awarded an aggregate of 1,186,006 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.